UNSPSC 51172014: Fenipentol

This classification denotes a cholagogue or choleretic agent with the molecular formula C11H16O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3FZE77O60, chemically known as 1-pentanol, 1-phenyl- but generally known as fenipentol, which bears US NIH Compound Identifier 3338. European Medicines Agency schedules Fenipentol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07567MIG.

UNSPSC 51172014 Fenipentol is a Commodity code representing pharmaceutical products purchased through state and local procurement channels for correctional, health, and general public-health purposes. Recent solicitations show state and local governments buying fenipentol primarily as part of broader drug-testing and pharmacy-benefit programs rather than as a standalone pharmaceutical ingredient. The scope of work includes supply of pharmaceutical products through authorized wholesaler networks, compliance with cGMP and FDA requirements, maintenance of expiration dates with minimum shelf-life standards, and pricing flexibility through multiple models. Issuing bodies include county community supervision departments, state health agencies, and multistate cooperative purchasing alliances, with activity concentrated in Texas and Minnesota.

Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026 for Offender Specimen Collection and Drug Testing Services with proposals due July 23, 2026, covering staffing at two collection sites, immunoassay screening with confirmation testing, and alternative testing methodologies for approximately 25,031 annual tests, with an estimated contract value of $600,000 and a two-year initial term. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 for Generic Multi Source Pharmaceuticals and OTC Products with proposals due March 26, 2026, requiring vendors to supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission issued RFI No. HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs for future procurement strategy development. Geographic activity centers on Texas and Minnesota, with MMCAP's cooperative vehicle spanning multiple participating states including Oregon.